SecBot SecBot

ASND

Ascendis Pharma A/S
Nasdaq· Pharmaceutical Preparations· Inc. G7· CIK 0001612042 Biotech & Drug Discovery
$272.04 −3.35 (−1.22%)
Nov 16 4:00 PM ET · prev $275.39
Market cap
$17.6B
Large cap
Consensus
Buy
96% Buy or better · 28 analysts
Median target
🔒 Subscribers only
1 year
+25.6%
from $216.56 · Nov 17
30 days
+20.8%
from $225.25
52-week range
$196.63–277.18
−2% from high · low Dec 9
Avg volume 20D
664.1K
shares / day
Short interest
3.00M
≈4.5% of shares · −4.3%
Days to cover
5.0
at average volume
Insider net
−$4.7M
2 buyers · 3 sellers · 12 mo
New fund stakes
29
Q2 2026 13F · 6 exits
Filing reports
35
analyzed by SecBot
SecBot read BULLISH 17 reports · 90 days
Balance 1 bearish · 8 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 12/17

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders bought $777.1K at an average $239.10. 3 insiders sold $5.5M. Price is 14% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 35 added (29 new), 12 trimmed or exited. Largest new: Westfield Capital Management $1.3B, American Century Companies $373.6M.

  • AnalystsBULLISH

    27 of 28 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate $1.177 → $1.900 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.3% to 3.00M shares. 5.0 days to cover, ≈4.5% of shares.

  • TrendUPTREND

    12% above its 50-day average.

Who's buying

13F· Q2 2026
29
new positions
6
exits
$3.0B
in new stakes
FundMoveSharesValue
WESTFIELD CAPITAL MANAGEMENT CO LPNEW4,798,267$1.3B
BlackRock, Inc.DOUBLED2,211,833$589.9M
AMERICAN CENTURY COMPANIES INCNEW1,400,575$373.6M
PRICE T ROWE ASSOCIATES INC /MD/TRIM1,122,529$299.4M
PRINCIPAL FINANCIAL GROUP INCNEW873,502$233.0M
STATE STREET CORPDOUBLED513,969$137.1M
GEODE CAPITAL MANAGEMENT, LLCNEW403,151$107.5M
UBS Group AGNEW401,881$107.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

28 analysts
Buy 96% rate it Buy or better
Strong Buy11Buy16Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 13, 2026UBS
MAINTAIN
MAINTAINBuy
Nov 13, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Nov 13, 2026RBC Capital
REITERATE
REITERATEOutperform
Nov 13, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 13, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$777.1K
bought · 2 insiders
$5.5M
sold · 3 insiders
+13.8%
vs their $239.10 cost
DateInsiderTypeValue
Sep 8, 2026
Bodenhoff Mads
SVP & PAO
Sep 8, 2026
SELL$810.6K
Sep 8, 2026
Bodenhoff Mads
SVP & PAO
Sep 8, 2026
EXERCISE$330.0K
Sep 2, 2026
HOLTUG LARS
Director
Sep 2, 2026
SELL$62.3K
Aug 14, 2026
BIENAIME JEAN JACQUES
Director
Aug 14, 2026
BUY$270.4K
Aug 14, 2026
BIENAIME JEAN JACQUES
Director
Aug 14, 2026
BUY$222.2K
Jun 2, 2026
SMITH SCOTT THOMAS
EVP & Chief Financial Officer
Jun 2, 2026
BUY$21.9K
May 29, 2026
BIENAIME JEAN JACQUES
Director
May 29, 2026
BUY$22.4K
May 29, 2026
BIENAIME JEAN JACQUES
Director
May 29, 2026
BUY$44.5K

Earnings setup

Estimates
$1.90
EPS estimate, this quarter
+61%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$1.90$1.57–$2.71+64.3%$414.8M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

16 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
2,997,710
shares short
-4.3%
vs prior settlement
5.0
days to cover
≈4.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Ascendis Pharma filed its updated Articles of Association and disclosed a routine grant of 28,030 employee warrants at…
6-K · Impact 2/10
Nov 12, 2026 SEC
Ascendis Pharma reported Q3 2026 product revenue of EUR 366M (+89% YoY), driven by YORVIPATH (EUR 291M, +103% YoY)…
6-K · Impact 6/10
Nov 12, 2026 Earnings
Ascendis Pharma Reports Third Quarter 2026 Financial Results
COPENHAGEN, Denmark, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno
Sep 8, 2026 Insider
Bodenhoff Mads sold 3,000 shares
SVP & PAO @ $270.19 ($810.6K)
Sep 8, 2026 Insider
Bodenhoff Mads acquired via exercise 3,000 shares
SVP & PAO @ $110.00 ($330.0K)
Sep 2, 2026 Insider
HOLTUG LARS sold 236 shares
Director @ $264.13 ($62.3K)
Aug 6, 2026 Press
Ascendis Pharma released positive Phase 2 COACH trial data showing its TransCon CNP + TransCon hGH combination therapy…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

35 filings · 6 press releases · 21 bullish · 1 bearish · 13 neutral
All ASND filing & press-release reports (41)